FIND OUT MORE
Despite the progress and unprecedented efficacy of existing immunotherapy drugs most patients either fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered tumor escape and resistance mechanisms and are developing new candidates designed to overcome resistance to currently available therapies.
Nectin’s pipeline includes innovative first-in-class and best-in-class programs, utilizing internal expertise as well as collaborative efforts.
Diverse pipeline of targeted immunotherapies including Novel immuno-oncology (IO) antibodies and ADCs.
PVR expression is emerging as an important rate limiting factor for approved ICI’s. Our Anti-PVR asset enters clinical trials in 2022.
If you share our passion for developing novel therapeutics to address difficult-to-treat cancers join us: